Alkermes Plc · NASDAQ:ALKS
Alkermes — Merger or Acquisition (October 2025)
13 slides from Alkermes's merger presentation, Oct 22, 2025
Slide 1: Proposed Acquisition of Avadel Pharmaceuticals plc
Proposed Acquisition of Avadel Pharmaceuticals plc October 22, 2025
Slide 2: No Offer or Solicitation
NO OFFER OR SOLICITATION This presentation is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities,
Slide 3: Statement Required by the Irish Takeover Rules
STATEMENT REQUIRED BY THE IRISH TAKEOVER RULES The directors of Alkermes accept responsibility for the information contained in this presentation. To the best of the knowledge and belief of the directors of Alkermes (who have taken all reasonable care to ensure that such is the case), the informatio
Slide 4: General
GENERAL Appendix I to the Rule 2.7 announcement issued jointly by Alkermes and Avadel on October 22, 2025 contains further details of the sources and bases of information set out in this presentation. Certain financial and other information concerning Avadel contained in this presentation has been e
Slide 5: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc’s (“Alkermes”) expectations
Slide 6: Acquisition of Avadel Offers Strong Strategic and Financial Benefits
Acquisition of Avadel Offers Strong Strategic and Financial Benefits* Augments revenue growth profile and diversifies Alkermes’ commercial portfolio with a new 1 high-growth product, LUMRYZ (sodium oxybate) Accelerates Alkermes’ commercial entry into sleep medicine market and provides strong foundat
Slide 7: Avadel Pharmaceuticals plc: A Leader in Sleep Medicine
Avadel Pharmaceuticals plc: A Leader in Sleep Medicine • Nasdaq: AVDL • Successfully developed and obtained regulatory approval for LUMRYZ (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age or older with narcolepsy • Secured LUMRYZ Orphan Drug
Slide 8: LUMRYZ: Strong Launch Trajectory; Significant Growth Opportunity in Sleep Medicine Market
LUMRYZ : Strong Launch Trajectory Reflects Differentiated Profile; Significant Growth Opportunity in Sleep Medicine Market • ~3,100 patients on LUMRYZ therapy (as of 6/30/25) of eligible patients state middle-of-the-night dosing • Estimated >50,000 oxybate-eligible patients ~40% is one of the main r
Slide 9: Avadel: Proven Commercial Capabilities Provide Strong Foundation for Growth
Avadel: Proven Commercial Capabilities Provide Strong Foundation for Growth Established high-performing commercial team in sleep medicine market driving LUMRYZ adoption and growth Deep expertise in reimbursement and market access in rare disease Specialized patient-support services to navigate compl
Slide 10: Advancing Innovation Together: Alkermes + Avadel Pipeline
Advancing Innovation Together: Alkermes + Avadel Pipeline* Discovery Preclinical Phase 1 Phase 2 Phase 3 Next Expected Milestone Alixorexton in Narcolepsy Type 1 Phase 3 initiation Q1 2026 Alixorexton in Narcolepsy Type 2 Phase 2 data Fall 2025 Alixorexton in Idiopathic Hypersomnia Phase 2 data Mid-
Slide 11: Alkermes: Strong Performance and Proven Capabilities Offer Strategic Fit for Avadel
Alkermes: Strong Performance and Proven Capabilities Offer Strategic Fit for Avadel Profitable business driven by proprietary commercial products Established Commercial Established Clinical Development Infrastructure in Complex Markets Capabilities and Exciting Pipeline Candidates Strong financial p
Slide 12: Transaction Summary
Transaction Summary Financial Terms Timing & Approvals All-cash transaction: $18.50 per share Approved by the Boards of Directors of both Alkermes and Avadel Contingent Value Right (CVR): potential additional payment of $1.50 per share in cash tied to final FDA approval of LUMRYZ in idiopathic hyper
Slide 13: www.alkermes.com
www.alkermes.com © 2025 Alkermes. All rights reserved.